Future Treatment of Diabetes - Tyrosine Kinase Inhibitors

Overview

Journal J Diabetes Metab Disord

Specialty Endocrinology

Date 2023 May 31

PMID 37255821

Authors

Aakash Kumar S

Snehal S Patel

Shreya Patel

Palak Parikh

Affiliations

Soon will be listed here.

Abstract

Background: Diabetes mellitus (DM) is a group of metabolic disorders that have an increased risk of macro and micro-vascular complications due to lipid dysfunction. The present drug treatments for the management of DM either have numerous side effects or do not have long-lasting therapeutic effects. So it is essential to find a newer class of drug for DM treatment.

Method: Broad information has been researched regarding Tyrosine kinase Inhibitors (TKIs) and their mechanism of action. They are proven for the management of various kinds of cancers. TKIs produce anti-hyperglycemic effects by acting on multiple targets such as c-Abl, Platelet-Derived Growth Factor Receptor (PDGFR), Vascular Endothelial Growth Factor Receptor (VEGFR), Epidermal Growth Factor Receptor (EGFR), and c-Kit.

Result: This family of drugs blocks numerous tyrosine kinases by acting as a partial agonist of PPAR-γ receptors and results in an anti-diabetic effect by improving insulin sensitivity and glucose disposal rate.

Conclusion: Therefore, it is said that TKI drugs will be great potential for the treatment of Diabetes. This review summarizes the possible targets of TKIs and TKIs being a potential drug class in the management of Diabetes mellitus.

Citing Articles

Slow progression of type 1 diabetes associated with pembrolizumab and lenvatinib combination therapy in a patient with probable slowly progressive type 1 diabetes mellitus and endometrial cancer.

Hazekawa I, Ishii N Diabetol Int. 2025; 16(1):169-174.

PMID: 39877434 PMC: 11769916. DOI: 10.1007/s13340-024-00771-0.

References

Hagerkvist R, Sandler S, Mokhtari D, Welsh N . Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J. 2006; 21(2):618-28. DOI: 10.1096/fj.06-6910com. View

Blay J, von Mehren M . Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin Oncol. 2011; 38 Suppl 1:S3-9. PMC: 4004101. DOI: 10.1053/j.seminoncol.2011.01.016. View

Pasadyn S, Knabel D, Fernandez A, Warren C . Cutaneous adverse effects of biologic medications. Cleve Clin J Med. 2020; 87(5):288-299. DOI: 10.3949/ccjm.87a.19119. View

Li Y, Gao Z, Qu X . The adverse effects of sorafenib in patients with advanced cancers. Basic Clin Pharmacol Toxicol. 2014; 116(3):216-21. DOI: 10.1111/bcpt.12365. View

Xia C, Zhang P, Li S, Yuan L, Xia T, Xie C . C-Abl inhibitor imatinib enhances insulin production by β cells: c-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2. PLoS One. 2014; 9(5):e97694. PMC: 4023982. DOI: 10.1371/journal.pone.0097694. View

Tremolada G, Lattanzio R, Mazzolari G, Zerbini G . The therapeutic potential of VEGF inhibition in diabetic microvascular complications. Am J Cardiovasc Drugs. 2007; 7(6):393-8. DOI: 10.2165/00129784-200707060-00002. View

Louvet C, Szot G, Lang J, Lee M, Martinier N, Bollag G . Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A. 2008; 105(48):18895-900. PMC: 2596241. DOI: 10.1073/pnas.0810246105. View

Fred R, Boddeti S, Lundberg M, Welsh N . Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells. Clin Sci (Lond). 2014; 128(1):17-28. DOI: 10.1042/CS20130560. View

Fox L, Cummins K, Costello B, Yeung D, Cleary R, Forsyth C . The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia. Blood Adv. 2018; 1(13):802-811. PMC: 5727806. DOI: 10.1182/bloodadvances.2016003889. View

10.

Abbas A, Blandon J, Rude J, Elfar A, Mukherjee D . PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations. Cardiovasc Hematol Agents Med Chem. 2012; 10(2):124-34. DOI: 10.2174/187152512800388948. View

11.

Li Z, Li Y, Overstreet J, Chung S, Niu A, Fan X . Inhibition of Epidermal Growth Factor Receptor Activation Is Associated With Improved Diabetic Nephropathy and Insulin Resistance in Type 2 Diabetes. Diabetes. 2018; 67(9):1847-1857. PMC: 6110321. DOI: 10.2337/db17-1513. View

12.

Justice C, Derbala M, Baich T, Kempton A, Guo A, Ho T . The Impact of Pazopanib on the Cardiovascular System. J Cardiovasc Pharmacol Ther. 2018; 23(5):387-398. PMC: 6257996. DOI: 10.1177/1074248418769612. View

13.

Szalek E, Karbownik A, Sobanska K, Grabowski T, Polom W, Lewandowska M . The pharmacokinetics and hypoglycaemic effect of sunitinib in the diabetic rabbits. Pharmacol Rep. 2014; 66(5):892-6. DOI: 10.1016/j.pharep.2014.05.011. View

14.

Breccia M, Muscaritoli M, Cannella L, Stefanizzi C, Frustaci A, Alimena G . Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res. 2008; 32(10):1626-8. DOI: 10.1016/j.leukres.2008.01.015. View

15.

Lane M, Hresko R, Kaestner K, Liao K, Janicot M, Hoffman R . Insulin-receptor tyrosine kinase and glucose transport. Diabetes Care. 1990; 13(6):565-75. DOI: 10.2337/diacare.13.6.565. View

16.

Franklin M, Burns L, Perez S, Yerragolam D, Makenbaeva D . Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US. Curr Med Res Opin. 2017; 34(2):353-360. DOI: 10.1080/03007995.2017.1399870. View

17.

Althubiti M, Almaimani R, Eid S, Elzubaier M, Refaat B, Idris S . BTK targeting suppresses inflammatory genes and ameliorates insulin resistance. Eur Cytokine Netw. 2021; 31(4):168-179. DOI: 10.1684/ecn.2020.0454. View

18.

Jia D, DU Z, Liu S, Liu H, Wang F, Ling E . c-Abl is involved in high glucose-induced apoptosis in embryonic E12.5 cortical neural progenitor cells from the mouse brain. J Neurochem. 2008; 106(4):1720-30. DOI: 10.1111/j.1471-4159.2008.05533.x. View

19.

Schwandt A, Wood L, Rini B, Dreicer R . Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma. Onco Targets Ther. 2010; 2:51-61. PMC: 2886329. DOI: 10.2147/ott.s4052. View

20.

Masood A, Kancha R, Subramanian J . Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib. Semin Oncol. 2019; 46(3):271-283. DOI: 10.1053/j.seminoncol.2019.08.004. View